Skip to main content
Cell
Mechanisms of long COVID and the path toward therapeutics.
Serotonin reduction in post-acute sequelae of viral infection.
Directly observing therapy: a new view of drug tolerance in tuberculosis.
Who benefits from granulomas, mycobacteria or host?
Viral latency in HIV disease.
HIV-1: the infective process in vivo.
Endoproteolytic cleavage of gp160 is required for the activation of human immunodeficiency virus.
